The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | The management of advanced phase MPNs
Abdulraheem Yacoub, MD, The University of Kansas, Westwood, KS, shares some insights into the management of accelerated phase myeloproliferative neoplasms (MPN-AP) and the need to design and conduct more clinical trials for patients with advanced disease. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Advisory role: Incyte, CTI Pharma , Pharmaessentia, Pfizer, Novartis, ACCELERON PHARMA, Agios ABBVIE, Apellis, Gilead, Notable Labs. Research Support: CTI Pharma, Stemline Therapeutics
